Literature DB >> 28754267

Efficient production and optimization of E7 oncoprotein from Iranian human papillomavirus type 16 in Lactococcus lactis using nisin-controlled gene expression (NICE) system.

Amir Hossein Mohseni1, Vadood Razavilar2, Hossein Keyvani3, Mohammad Reza Razavi4, Ramazan Ali Khavari-Nejad5.   

Abstract

The present work was aimed at investigating the expression and optimization of a human papillomavirus (HPV) type 16 gene encoding oncoprotein E7 in Lactococcus lactis. We genetically engineered Lactococcus lactis using nisin-controlled gene expression (NICE) system pNZ8148 to express the native and codon optimized E7 oncogenes isolated from Iranian HPV-16. The results of optimizing fermentation showed, the concentration of produced protein was expressively improved by 10 ng/mL nisin after 3.5, and 4 h induction for NZ9000 harboring the codon-optimized, and native E7 respectively. Furthermore the recombinant NZ9000 strains expressed rE7 by maximum value of 4.7 (Codon-optimized), and 1.82 μg/mL (Native) in static flask experiments at initial glucose concentrations of 50 and 75 g/L respectively. The rE7 yield was further enriched in batch fermenter experiments using controlled pH. Thus, the overall production of rE7 under optimized conditions accumulated in the cytoplasm to nearly 33.25 μg/mL by L. lactis NZ9000 containing codon-optimized E7, which was over ∼2.7-fold higher compared to the NZ9000 having native E7 strain (12.01 μg/mL). Accordingly, the maximum biomass production was calculated 4.87, and 1.51 g/L respectively.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  E7; Human papillomavirus type 16; Lactococcus lactis; pNZ8148

Mesh:

Substances:

Year:  2017        PMID: 28754267     DOI: 10.1016/j.micpath.2017.07.039

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  5 in total

1.  Extracellular overproduction of E7 oncoprotein of Iranian human papillomavirus type 16 by genetically engineered Lactococcus lactis.

Authors:  Amir Hossein Mohseni; Sedigheh Taghinezhad-S; Hossein Keyvani; Vadood Razavilar
Journal:  BMC Biotechnol       Date:  2019-01-24       Impact factor: 2.563

2.  Phase 1 Safety and Immunogenicity Trial of Recombinant Lactococcus lactis Expressing Human Papillomavirus Type 16 E6 Oncoprotein Vaccine.

Authors:  Sedigheh Taghinezhad-S; Amir Hossein Mohseni; Hossein Keyvani; Mohammad Reza Razavi
Journal:  Mol Ther Methods Clin Dev       Date:  2019-08-29       Impact factor: 6.698

Review 3.  Plasmid Replicons for the Production of Pharmaceutical-Grade pDNA, Proteins and Antigens by Lactococcus lactis Cell Factories.

Authors:  Sofia O D Duarte; Gabriel A Monteiro
Journal:  Int J Mol Sci       Date:  2021-01-30       Impact factor: 5.923

Review 4.  Probiotic-Based Vaccines May Provide Effective Protection against COVID-19 Acute Respiratory Disease.

Authors:  Sedigheh Taghinezhad-S; Amir Hossein Mohseni; Luis G Bermúdez-Humarán; Vincenzo Casolaro; Naima G Cortes-Perez; Hossein Keyvani; Jesus Simal-Gandara
Journal:  Vaccines (Basel)       Date:  2021-05-06

Review 5.  Twenty years of research on HPV vaccines based on genetically modified lactic acid bacteria: an overview on the gut-vagina axis.

Authors:  Sedigheh Taghinezhad-S; Hossein Keyvani; Luis G Bermúdez-Humarán; Gilbert G G Donders; Xiangsheng Fu; Amir Hossein Mohseni
Journal:  Cell Mol Life Sci       Date:  2020-09-26       Impact factor: 9.261

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.